Stock CLAL BIOTECHNOLOGY INDUSTRIES LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Clal Biotechnology Industries Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

IL0011042806

Investment Holding Companies

Financials

Sales 2022 370K 97.3K 37M Sales 2023 104K 27.35K 10.4M Capitalization 62.27M 16.38M 6.23B
Net income 2022 -61M -16.04M -6.1B Net income 2023 -31M -8.15M -3.1B EV / Sales 2022 331 x
Net Debt 2022 23.85M 6.27M 2.38B Net Debt 2023 22.4M 5.89M 2.24B EV / Sales 2023 814 x
P/E ratio 2022
-1.6 x
P/E ratio 2023
-2.01 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 34.65%
More Fundamentals * Assessed data

Chart Clal Biotechnology Industries Ltd.

Dynamic Chart

Latest news about Clal Biotechnology Industries Ltd.

Clal Biotechnology Industries Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Clal Biotechnology Industries Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Clal Biotechnology Industries Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Clal Biotechnology Industries Ltd. announced that it expects to receive ILS 24.999999 million in funding from Meitav Dash Providence and Pension Ltd. CI
Clal Biotechnology Industries Ltd. announced that it expects to receive ILS 5 million in funding CI
Clal Biotechnology Industries Ltd. announced that it expects to receive ILS 20 million in funding from Yelin Lapidot Provident Funds Management Ltd., Yelin Lapidot - Mutual Funds Management Ltd. CI
Clal Biotechnology Seeks Investments CI
Clal Biotechnology Industries Ltd. Appoints Ofer Gonen as Permanent CEO CI
Clal Biotechnology Industries Ltd. Appoints Julian Adams Ph.D. as President and Chief Science Officer CI
Investment Arm of Cybele Investment House Ltd and Investment Arm of Victor Tshuba & Co. Law Office acquired 58% stake in D-Pharm LTD. from Clal Biotechnology Industries Ltd. for ILS 0.31 million. CI
More news

Managers and Directors - Clal Biotechnology Industries Ltd.

Managers TitleAgeSince
Assaf Segal CEO
 Chief Executive Officer 51 15-06-30
Liat Nissan DFI
 Director of Finance/CFO 46 -
Arnon Aharon CTO
 Chief Tech/Sci/R&D Officer 55 21-12-31
Members of the board TitleAgeSince
Avraham Matityahu Fischer CHM
 Chairman 67 03-05-08
Yuval Yanai BRD
 Director/Board Member 71 15-11-17
Gad Keren BRD
 Director/Board Member 73 20-02-16
More insiders

Company Profile

Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.
Sector
Investment Holding Companies
More about the company

Sector Other Holding Companies

1st Jan change Capi.
INVESTOR AB Stock Investor AB
+14.43% 75.79B
KOÇ HOLDING Stock Koç Holding
+50.49% 16.52B
INVESTMENT AB LATOUR Stock Investment AB Latour
+1.22% 16.48B
AB INDUSTRIVÄRDEN Stock AB Industrivärden
+4.96% 14.05B
L E LUNDBERGFÖRETAGEN AB Stock L E Lundbergföretagen AB
-2.32% 12.51B
HAL TRUST Stock HAL Trust
+9.49% 12.07B
BAJAJ HOLDINGS & INVESTMENT LIMITED Stock Bajaj Holdings & Investment Limited
+6.90% 10.98B
MERITZ FINANCIAL GROUP INC. Stock Meritz Financial Group Inc.
+31.64% 9.89B
GROUPE BRUXELLES LAMBERT SA Stock Groupe Bruxelles Lambert SA
-3.12% 9.7B
Other Holding Companies
  1. Stock Market
  2. Equities
  3. CBI Stock
  4. Stock